CytoDyn, Treatment Conference-Bound

CytoDyn, Treatment Conference-Bound

By: Dylan Sikes – News

Wednesday, February 27, 2019

It’s certainly creating a great deal of hype, and investors and the medical community alike are hoping it’s not hype that turns into hyperbole.

Vancouver, Wash.-based CytoDyn Inc. (OTC:CYDY) shook things up Wednesday among medical research types, on word the late-stage biotechnology company is scheduled in early March to present its latest discovery at the Conference on Retroviruses and Opportunistic Infections in Seattle.

CYDY is developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, and announced Wednesday that data from its study of leronlimab will be prominently featured. 

Leronlimab is a once-weekly, subcutaneous injection that blocks HIV-1 from entering and infecting human cells by binding to the CCR5 receptor with high affinity. 

CEO Nader Pourhassen says, “CytoDyn’s commitment to providing groundbreaking therapeutic advances for those in need has never been stronger. We remain highly encouraged by the continued clinical and regulatory progress to bring the next generation HIV treatment to patients.”

The Seattle conference brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

CYDY shares moved into Wednesday afternoon trading ahead two cents, or 4%, to 52 cents, on volume 298,000 shares. 

Copyright © 2019 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Sugar Demand Helps This Firm Report Solid Q4 Results
Fed’s Preferred Inflation Measure Shows Cooling
Dual-Listed Junior Miner Announces Progress in Uranium Quest
Most Popular
FREE Newsletter

Back to Top